Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
RNA

RNA - Avidity Biosciences Inc Stock Price, Fair Value and News

39.97USD+1.61 (+4.20%)Market Closed

Market Summary

RNA
USD39.97+1.61
Market Closed
4.20%

RNA Alerts

  • 3 major insider sales recently.

RNA Stock Price

View Fullscreen

RNA RSI Chart

RNA Valuation

Market Cap

3.8B

Price/Earnings (Trailing)

-16.72

Price/Sales (Trailing)

141.53

Price/Free Cashflow

-26.58

RNA Price/Sales (Trailing)

RNA Profitability

Return on Equity

-27.52%

Return on Assets

-24.03%

Free Cashflow Yield

-3.76%

RNA Fundamentals

RNA Revenue

Revenue (TTM)

27.0M

Rev. Growth (Yr)

58.67%

Rev. Growth (Qtr)

-76.19%

RNA Earnings

Earnings (TTM)

-228.7M

Earnings Growth (Yr)

-31.42%

Earnings Growth (Qtr)

-13.92%

Breaking Down RNA Revenue

Last 7 days

53.5%

Last 30 days

38.3%

Last 90 days

63.7%

Trailing 12 Months

227.9%

How does RNA drawdown profile look like?

RNA Financial Health

Current Ratio

12.47

RNA Investor Care

Shares Dilution (1Y)

35.04%

Diluted EPS (TTM)

-2.96

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202427.0M000
20235.4M10.6M10.9M25.7M
20227.8M6.8M5.9M5.0M
20218.1M9.2M9.6M8.7M
20203.7M5.0M6.1M6.8M
201901.0M1.7M2.3M
2018000379.0K

Tracking the Latest Insider Buys and Sells of Avidity Biosciences Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 04, 2024
boyce sarah
acquired
34,720
1.24
28,000
president and ceo
Jun 04, 2024
boyce sarah
sold
-767,780
27.4207
-28,000
president and ceo
May 20, 2024
levin arthur a
acquired
6,200
1.24
5,000
-
May 20, 2024
levin arthur a
sold
-149,481
29.8962
-5,000
-
May 14, 2024
maclean michael f
acquired
661,500
8.82
75,000
chief financial officer
May 14, 2024
maclean michael f
sold
-2,121,040
28.2806
-75,000
chief financial officer
May 07, 2024
boyce sarah
sold
-715,050
25.5375
-28,000
president and ceo
May 07, 2024
boyce sarah
acquired
34,720
1.24
28,000
president and ceo

1–10 of 50

Which funds bought or sold RNA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
920,000
1,480,000
-%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
new
-
533,000
533,000
-%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
new
-
15,466,700
15,466,700
0.07%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
78.52
312,430
390,430
0.05%
May 16, 2024
ALETHEA CAPITAL MANAGEMENT, LLC
reduced
-10.99
11,678,400
19,413,000
15.77%
May 16, 2024
JANE STREET GROUP, LLC
added
59.3
2,220,240
2,856,040
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
10.19
1,238,720
1,826,570
-%
May 15, 2024
Oracle Alpha Inc.
reduced
-19.07
150,805
268,419
0.48%
May 15, 2024
Nebula Research & Development LLC
sold off
-100
-340,162
-
-%
May 15, 2024
Voya Investment Management LLC
reduced
-16.26
360,765
625,776
-%

1–10 of 48

Are Funds Buying or Selling RNA?

Are funds buying RNA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RNA
No. of Funds

Unveiling Avidity Biosciences Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 06, 2024
ra capital management, l.p.
5.1%
4,895,959
SC 13G
Mar 11, 2024
price t rowe associates inc /md/
12.1%
9,656,852
SC 13G/A
Mar 01, 2024
rtw investments, lp
9.99%
9,659,809
SC 13D/A
Feb 14, 2024
price t rowe associates inc /md/
9.3%
6,917,910
SC 13G/A
Feb 14, 2024
ra capital management, l.p.
3.3%
2,454,533
SC 13G/A
Feb 13, 2024
vanguard group inc
5.46%
4,043,179
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 02, 2024
cowen financial products llc
7.6%
5,628,103
SC 13G/A
Jan 25, 2024
blackrock inc.
8.8%
6,496,593
SC 13G/A
Jan 24, 2024
rtw investments, lp
8.4%
6,701,489
SC 13D/A

Recent SEC filings of Avidity Biosciences Inc

View All Filings
Date Filed Form Type Document
Jun 13, 2024
144
Notice of Insider Sale Intent
Jun 13, 2024
144
Notice of Insider Sale Intent
Jun 12, 2024
144
Notice of Insider Sale Intent
Jun 12, 2024
144
Notice of Insider Sale Intent
Jun 12, 2024
144
Notice of Insider Sale Intent
Jun 12, 2024
424B5
Prospectus Filed
Jun 12, 2024
8-K
Current Report
Jun 05, 2024
4
Insider Trading
Jun 04, 2024
144
Notice of Insider Sale Intent
May 21, 2024
4
Insider Trading

Peers (Alternatives to Avidity Biosciences Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
55.6B
6.8B
13.11% 15.14%
-9.32
8.12
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.2B
2.0B
8.19% -19.39%
-60.95
10.1
75.20% 68.82%
16.0B
2.5B
5.74% -10.79%
77.84
6.47
13.74% 186.89%
14.1B
3.8B
9.90% 2.05%
18.89
3.74
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.17% 71.70%
-9.93
48.09
54.84% -28.31%
5.2B
524.1M
3.28% -53.81%
-12.38
9.85
394.93% 39.61%
3.4B
251.0M
-6.27% -10.41%
-11.62
13.72
73.58% -86.73%
3.3B
240.7M
15.67% -25.01%
-6.96
12.77
-1.03% -213.92%
2.5B
813.8M
1.62% -37.45%
-1.5K
3.07
56.43% 98.83%
2.1B
996.6M
11.65% 94.95%
-5.3
2.12
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-7.16% 29.42%
27.77
4.4
60.38% -34.49%
564.4M
881.7K
22.84% 567.64%
-16.72
481.06
-77.61% 33.36%
244.6M
4.2M
-17.34% 57.33%
-1.96
58.8
-66.30% 48.24%
22.1M
2.1M
36.17% 271.01%
-0.95
7.61
-13.45% 69.54%

Avidity Biosciences Inc News

Latest updates
Defense World109 minutes ago

Avidity Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q4
Revenue-76.2%3,54314,8782,8185,7712,23387.002,4826111,7951,9792,1632,6072,7042,1421,7461,5411,3581,445650224-
Operating Expenses17.1%80,73068,93661,44354,95059,82955,99447,41148,47736,25540,39931,44328,97426,56118,43513,21211,9097,5087,4925,8564,129-
  S&GA Expenses-13.8%13,89816,11913,72912,27812,06410,38410,0948,6888,5677,4316,6126,2685,8844,8163,7572,9251,9641,8477571,596-
  R&D Expenses26.5%66,83252,81747,71442,67247,76545,61037,31739,78927,68832,96824,83122,70620,67713,6199,4558,9845,5445,6455,0992,533-
Interest Expenses----------------13178.004,3381,4621,215-
Net Income-13.9%-68,855-60,443-52,358-47,025-52,394-50,471-43,599-45,690-34,235-38,538-29,274-26,353-23,844-16,275-11,439-10,556-6,085-10,401-6,668-5,116-
Net Income Margin-2.5%-8.47*-8.26*-18.54*-18.30*-35.50*-34.97*-27.45*-21.63*-16.55*-13.58*-9.96*-8.47*---------
Free Cashflow-555.9%-71,29515,638-37,714-50,429-50,787-40,039-31,852-36,868-30,332-27,922-21,582-28,843---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22019Q4
Assets51.4%95162957361161463943142142142842629131533434635597.00
  Current Assets52.9%93461155559559762341440440541142228731233234435496.00
    Cash Equivalents154.7%47118586.0015411934114412514032141027630132234135295.00
  Net PPE3.3%9.008.008.008.008.006.006.006.005.005.003.003.002.001.001.001.001.00
Liabilities-5.6%12112856.0052.0055.0061.0054.0046.0045.0046.0031.0026.0029.0028.0026.0025.0028.00
  Current Liabilities-7.1%75.0081.0049.0045.0048.0052.0043.0034.0031.0030.0022.0016.0018.0015.0014.0012.0010.00
Shareholder's Equity65.9%831501517559559578377374376381395264286306320330-
  Retained Earnings-12.1%-639-570-510-457-410-358-308-264-218-184-146-116-90.40-66.54-50.26-38.83-22.18
  Additional Paid-In Capital37.3%1,4711,0711,0301,020971939689642597566541381376373370369-43.17
Accumulated Depreciation12.3%6.005.00---3.00-----------
Shares Outstanding20.6%96.0079.0074.0074.0070.0070.0053.0049.0048.0041.0039.0038.00-----
Float----811---739---798---887-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q4
Cashflow From Operations-526.5%-70,38016,501-36,791-49,807-48,967-39,189-31,959-35,546-29,574-26,215-20,782-28,135-19,681-13,073-9,113-7,791-7,140-5,019-5,885--
  Share Based Compensation4.7%10,3069,8459,8209,4539,1047,3077,0866,5086,2384,5164,5504,2893,7011,8781,29668744935122.00--
Cashflow From Investing-164.2%-32,74751,040-31,47946,049-195,680-7,76810,932-17,644-175,475-84,064-8002,872-525-6,930-845--10.00-91.00-14.00--
Cashflow From Financing1121.2%389,44531,89140.0038,97222,961243,65439,62038,78424,11320,714155,17241317.00450-1,346271,6101,32371,824-712--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

RNA Income Statement

2024-03-31
Condensed Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Collaboration revenue$ 3,543$ 2,233
Operating expenses:  
Research and development66,83247,765
General and administrative13,89812,064
Total operating expenses80,73059,829
Loss from operations(77,187)(57,596)
Other income (expense):  
Interest income8,4335,516
Other expense(101)(314)
Total other income8,3325,202
Net loss$ (68,855)$ (52,394)
Net loss per share, basic (in dollars per share)$ (0.79)$ (0.74)
Net loss per share, diluted (in dollars per share)$ (0.79)$ (0.74)
Weighted-average shares outstanding, basic (in shares)87,21270,433
Weighted-average shares outstanding, diluted (in shares)87,21270,433
Other comprehensive income (loss):  
Net unrealized gains (losses) on marketable securities$ (589)$ 1,169
Comprehensive loss$ (69,444)$ (51,225)

RNA Balance Sheet

2024-03-31
Condensed Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 471,400$ 185,082
Marketable securities444,473410,269
Prepaid and other assets18,60115,956
Total current assets934,474611,307
Property and equipment, net8,6558,381
Restricted cash295295
Right-of-use assets7,6258,271
Other assets425301
Total assets951,474628,555
Current liabilities:  
Accounts payable and accrued liabilities37,33034,341
Accrued compensation7,79614,335
Lease liabilities, current portion3,7263,639
Deferred revenue, current portion26,10328,365
Total current liabilities74,95580,680
Lease liabilities, net of current portion5,4216,213
Deferred revenue, net of current portion40,19940,898
Total liabilities120,575127,791
Commitments and contingencies (Note 7)
Stockholders’ equity:  
Common stock, $0.0001 par value; authorized shares – 400,000; issued and outstanding shares – 95,594 and 79,275 at March 31, 2024 and December 31, 2023, respectively108
Additional paid-in capital1,470,9721,071,395
Accumulated other comprehensive income (loss)(464)125
Accumulated deficit(639,619)(570,764)
Total stockholders’ equity830,899500,764
Total liabilities and stockholders’ equity$ 951,474$ 628,555
RNA
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy, which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
 CEO
 WEBSITEaviditybiosciences.com
 INDUSTRYBiotechnology
 EMPLOYEES186

Avidity Biosciences Inc Frequently Asked Questions


What is the ticker symbol for Avidity Biosciences Inc? What does RNA stand for in stocks?

RNA is the stock ticker symbol of Avidity Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Avidity Biosciences Inc (RNA)?

As of Thu Jun 13 2024, market cap of Avidity Biosciences Inc is 3.82 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RNA stock?

You can check RNA's fair value in chart for subscribers.

What is the fair value of RNA stock?

You can check RNA's fair value in chart for subscribers. The fair value of Avidity Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Avidity Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RNA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Avidity Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether RNA is over valued or under valued. Whether Avidity Biosciences Inc is cheap or expensive depends on the assumptions which impact Avidity Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RNA.

What is Avidity Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, RNA's PE ratio (Price to Earnings) is -16.72 and Price to Sales (PS) ratio is 141.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RNA PE ratio will change depending on the future growth rate expectations of investors.